There's still only one biosimilar on the US market, but the third quarter earnings calls this year may have marked the point where updates about them became routine, with firms discussing the products just as they would any pipeline project or potential competitor.
Novartis AG, for one, confirmed during its third quarter earnings call that its application for a biosimilar version of Amgen’s Neulasta (pegfilgrastim) will be tied up at FDA until at least sometime in 2018. Sandoz Inc., a unit of Novartis, filed the application in September 2015 and in July reported that it had received a complete response letter from FDA
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?